Minerva Neurosciences reported progress in advancing roluperidone through pivotal clinical trials targeting negative symptoms of schizophrenia, signaling a critical phase in its CNS-focused pipeline. Its opt-out of the Janssen co-development deal transformed seltorexant royalties into a recurring revenue stream, partially offsetting operating costs without further development expenses. As a clinical-stage biopharma company, Minerva depends on equity financing and milestone-based payments while navigating patent protection and regulatory challenges. The company's liquidity remains sufficient near term, though sustaining operations hinges on future capital raises aligned with clinical milestones and royalty inflows.